Can a patient with new onset atrial fibrillation (AFib) and normal ventricular response, with a history of stroke while on Plavix (clopidogrel), start Xarelto (rivaroxaban)?

Rivaroxaban (Xarelto) for New Onset Atrial Fibrillation with History of Stroke

Yes, this patient with new onset atrial fibrillation and history of stroke while on Plavix should start Xarelto (rivaroxaban) as oral anticoagulation is superior to antiplatelet therapy alone for stroke prevention in this high-risk scenario. 1, 2, 3

Rationale for Anticoagulation

• Patient has two critical risk factors:

  • New onset atrial fibrillation (AF)
  • Previous stroke while on antiplatelet therapy (Plavix/clopidogrel)

• These factors place the patient at high risk for recurrent stroke with a CHA₂DS₂-VASc score of at least 2 (previous stroke alone contributes 2 points)

• The 2019 AHA/ACC/HRS guidelines strongly recommend oral anticoagulation for patients with AF and prior stroke (Class I recommendation) 1, 3

• The fact that the patient had a stroke while on Plavix indicates that antiplatelet therapy alone was insufficient for stroke prevention

Benefits of Rivaroxaban (Xarelto) in This Case

• Rivaroxaban has been shown to reduce stroke risk by 19% compared to warfarin in real-world settings, with particularly significant reductions (48%) in severe strokes 4

• For patients with AF at increased risk of stroke (CHA₂DS₂-VASc ≥2), rivaroxaban 15-20mg daily (dose based on renal function) is reasonable to reduce bleeding risk compared to triple therapy 1

• Rivaroxaban offers advantages of:

  • Fixed dosing without need for regular INR monitoring
  • Once-daily administration
  • Fewer food and drug interactions than warfarin 5

Dosing Considerations

• Standard dose: 20mg once daily with food
• For patients with CrCl 15-50 mL/min: 15mg once daily with food
• Avoid if CrCl <15 mL/min 6

Important Cautions

• Assess renal function before initiating therapy
• Rivaroxaban is contraindicated in patients with mechanical heart valves 3
• Bleeding risk is increased when combined with antiplatelet agents like Plavix 1, 3

Management Recommendations

1. Discontinue Plavix (clopidogrel) as combined antiplatelet and anticoagulant therapy substantially increases bleeding risk without providing additional benefit for most stroke patients 7

2. Start Xarelto (rivaroxaban) at appropriate dose based on renal function:

   • If CrCl >50 mL/min: 20mg once daily with food
   • If CrCl 15-50 mL/min: 15mg once daily with food 6

3. Monitor for bleeding complications and educate patient about signs of bleeding that require medical attention

4. Special considerations:

   • If the patient has recent coronary stenting, a cardiologist should be consulted as dual therapy (Xarelto plus single antiplatelet) may be needed for a limited time 8
   • If the patient has valvular AF (mechanical valves or moderate-severe mitral stenosis), warfarin would be preferred over Xarelto 3, 7

Common Pitfalls to Avoid

• Don't continue antiplatelet therapy alone: Clopidogrel (Plavix) alone or in combination with aspirin is inferior to oral anticoagulation for stroke prevention in AF 9

• Don't use triple therapy (anticoagulant plus dual antiplatelet therapy) unless absolutely necessary (e.g., recent coronary stenting) due to significantly increased bleeding risk 1

• Don't use reduced doses of rivaroxaban without appropriate renal indication, as this may reduce efficacy

By transitioning from Plavix to Xarelto, this patient will receive more effective stroke prevention therapy that is appropriate for their high-risk status with AF and prior stroke history.